Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Buying and holding stocks for long periods of time can generate market-beating results. Most individual stocks, however, aren't capable of delivering above-average results over the long haul.

Is Amgen Stock a Top Buy and Hold?

Horizon Pharma

Horizon Therapeutics reports better-than-expected Q2 results, easing concerns about the Amgen acquisition failing to close due to Horizon's business underperformance. Net sales of Tepezza have been a key issue, but positive label changes and phase 4 results are expected to drive demand, and the major headwinds are now behind. Krystexxa and Uplizna continue to show strong growth, adding value to the acquisition.

Improved Outlook For Horizon Therapeutics And Amgen

Amgen has many blockbuster drugs, including Enbrel, Prolia, and Otezla. Its growth rate hasn't been great recently, but acquisitions could help change that.

Could Amgen Stock Help You Become a Millionaire?

Amgen's established products declined while some of its best-selling drugs enjoyed growth.

Up 970-Fold Since Its IPO, Amgen Stock Could Be Overvalued

Amgen stock (NASDAQ: AMGN) has seen a 17% rise in a month, outperforming the broader S&P500 index, up 1%.

Is Amgen Stock Fully Valued After A 17% Rise In A Month?

Bristol-Myers

Johnson & Johnson

Merck

Pfizer

It's still unclear which drugs Medicare will select, but several companies have revealed in court filings that four of their medications are targets.

These 10 medications are likely targets for Medicare price negotiations this fall

Honeywell

Visa

Dow Jones Industrial Average stocks to check out in the stock market today.

3 Dow Jones Stocks To Watch In August 2023

Amgen's revenue and profits rose in Q2. The company's market-smashing dividend has growth ahead of it.

Want Rising Dividend Income? Buy Amgen Stock

CRISPR Therapeutics

Gilead Sciences

Many healthcare stocks suffer from COVID fatigue as profits fall amid a global decline in the virus' spread. But medical innovations and technological breakthroughs are rapidly transforming the healthcare landscape, and biotech stocks are garnering unprecedented attention in the investment community.

The 3 Best Biotech Stocks to Buy in August

Exelixis

Jazz Pharmaceuticals

The biotech industry proved itself resilient in the face of the COVID-19 pandemic. With research from Mckinsey, venture capitalist ( VC ) companies increased investments from 2,200 in 2016 to 3,100 in 2021 in biotechnology (biotech) startups.

3 Biotech Stocks You'll Regret Not Buying Soon

Boeing

Salesforce

Cisco Systems

Chevron

Disney

Dow Inc

Goldman Sachs

Intel

JPMorgan Chase & Co

Coca-Cola

Microsoft

NIKE

Travelers

Verizon

Walgreens

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.”–Dow Jones & Co. The highest-yield 10 stocks are August's Dogs of the Dow: CSCO, KO, GS, AMGN, CVX, IBM, DOW, MMM, WBA, and VZ, averaged a 4.63% annual yield. Thirty Dow stocks represent nine of eleven sectors. Dow Jones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated August net-gains ranged 15.75%-33.3%, topped by VZ 8/4/23.

Buy 2 August Dogs Of The Dow, Watch 5

The main benchmarks closed higher ahead of this week's key inflation update.

Stock Market Today: Dow Outperforms as Amgen, Boeing Gain Ground

AMGN has a long track record of top and bottom-line growth, with strong capital returns to shareholders. It recently reported a strong Q2 with a number of drugs seeing double-digit volume and sales growth. Amgen is also experiencing strong international growth, which could be bolstered by its pending acquisition of Horizon Therapeutics. Shares remain undervalued.

Amgen Gives You Growth, Dividend Growth, And Value

Amgen Inc. NASDAQ: AMGN delivered a solid earnings report after the market closed on August 3. Shareholders hope the results will be enough to reverse the fortunes of AMGN stock, down 12% in 2023.

Is Growth Priced into Amgen Stock after Earnings Beat?

Amgen faces stiffer competition, adverse exchange rates, and a waning Covid market. But the big biotech should be able to get past these various challenges.

1 Top Dividend Growth Stock to Buy on the Dip

Amgen (AMGN) beats Q2 estimates for earnings and sales. It slightly raises its earnings and sales guidance for 2023.

Amgen (AMGN) Q2 Earnings Beat Estimates, 2023 View Raised

Amgen (AMGN) came out with quarterly earnings of $5 per share, beating the Zacks Consensus Estimate of $4.44 per share. This compares to earnings of $4.65 per share a year ago.

Amgen (AMGN) Q2 Earnings and Revenues Top Estimates

Amgen beat second-quarter expectations Thursday and raised its outlook for the year, helping push Amgen stock higher in late action.

Amgen Beats Expectations, Raises Outlook With Horizon Takeover In The Wings

Shares of Amgen Inc. AMGN, +0.13% jumped 1.5% in after-hours trading Thursday, after the biotechnology giant reported record second-quarter earnings that rose above expectations and raised the full-year outlook, as volume growth offset a slight decline in prices. Net income rose to $1.38 billion, or $2.57 a share, from $1.32 billion, or $2.45 a share, in the year-ago period.

Amgen stock jumps after the biotech's record earnings beats expectations, and full-year outlook is raised

Amgen , which is facing U.S. Federal Trade Commission (FTC) delays to its planned acquisition of Horizon Therapeutics , on Thursday reported higher quarterly profit on strong sales of treatments for cholesterol, osteoporosis and other drugs.

Amgen quarterly revenue rises 6%, profit beats Street estimates

Positive Top-Line Results for Tarlatamab in Small Cell Lung Cancer Positive Top-Line Results for LUMAKRAS ® (Sotorasib) Plus Vectibix ® (Panitumumab) in Metastatic Colorectal Cancer THOUSAND OAKS, Calif. , Aug. 3, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2023.

AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS

Mondelez

Amgen, Microsoft, and Mondelez International have all been generously raising their payouts in recent years. These are growing businesses that generate strong profits, which enable them to boost their dividend payments.

3 Dividend Stocks That Hiked Payouts by 60% in Just 5 Years

THOUSAND OAKS, Calif. , Aug. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the third quarter of 2023.

AMGEN ANNOUNCES 2023 THIRD QUARTER DIVIDEND

THOUSAND OAKS, Calif. , July 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 3, 2023, after the close of the U.S. financial markets.

AMGEN ANNOUNCES WEBCAST OF 2023 SECOND QUARTER FINANCIAL RESULTS

Apple

Ardelyx

Celsius Holdings

Coinbase

DocGo

Diamond Offshore Drilling Inc

New Oriental Education & Technology Group

e.l.f. Beauty

Enphase Energy

Evolution Petroleum

Fluence Energy

FTC Solar

Genius Sports

GSX Techedu Inc.

Immunocore Holdings

Inter & Co Inc

MoonLake Immunotherapeutics

Noble Corp PLC

Two new Breakout Stocks for Week 31 curated by the MDA model for 10% short-term upside and additional model selections. This week two of four picks gained over 10% in less than a week with peak gains in CLLS +16.8% AUTL+15.5% but the portfolio failed to hold gains. The streak of weekly picks gaining over 10% in less than a week has increased to 255 out of 322 trading weeks (79.2%) not including multiple gainers or warning signals.

News for Amgen Stock (AMGN)